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are the standard of care in high-
income countries.10 Furthermore, 
there is compelling evidence that 
cytomegalovirus retinitis11 and 
systemic cytomegalovirus infection12 
are linked to mortality rates, and 
reasonable evidence that systemic 
treatment of cytomegalovirus 
retinitis will reduce mortality.13 How 
should valganciclovir be given to 
newly diagnosed patients with AIDS 
and cytomegalovirus retinitis? A 
common-sense starting point  (based 
on both standards of care in high-
income countries and extensive 
direct personal clinical experience) 
would be to provide valganciclovir 
900 mg twice a day for 2 weeks and 
then valganciclovir 900 mg once a 
day until three conditions are met: a 
minimum of 3 months has elapsed, 
active cytomegalovirus retinitis has 
completely resolved, and a good 
response to antiretroviral therapy has 
been achieved. The current practice 
of intraocular ganciclovir injection 
should be continued for the first 
2 weeks to provide local induction. 
The blood cell count should be 
monitored for leucopenia. It is 
important to preserve techniques of 
intraocular injection for patients who 
become cytopenic and for patients 
who might not be able to take 
oral drugs (comatose state, severe 
dysphagia, etc), or in whom the 
retinitis does not seem to respond 
promptly (including because of the 
development of resistant strains). 
Well designed operational research 
is needed to reﬁ ne this starting point. 
Research is also needed to find out 
whether prophylactic valganciclovir 
treatment in high-risk patients 
might reduce AIDS mortality as 
well as blindness, as substantial 
data suggest.14,15 WHO leadership is 
needed to provide cytomegalovirus 
diagnosis and treatment guidelines, 
support countries’ eﬀ orts to scale up 
diagnosis, and explore the possibility 
of integration of routine eye screening 
with indirect ophthalmoscopy into 
routine care for all patients first 
We urge WHO to act 
on cytomegalovirus 
retinitis
On Nov 11, 2013, The Lancet Global 
Health published an analysis of the 
causes of vision loss 1990–2010.1 
This analysis does not mention 
the risk of vision loss as a result of 
untreated cytomegalovirus retinitis 
in people with HIV, despite the 
infection’s continued prevalence 
in low-income and middle-income 
countries. Cytomegalovirus disease 
was one of three unusual infections 
in the report by the US Centers for 
Disease Control and Prevention2 that 
marked the oﬃ  cial start of the AIDS 
epidemic on June 5, 1981. Before the 
availability of antiretroviral therapy, 
cytomegalovirus retinitis, the most 
common manifestation of AIDS-
related cytomegalovirus infection, 
aﬀ ected a third of patients with AIDS 
and accounted for more than 90% of 
AIDS-related blindness. 
Sadly, cytomegalovirus retinitis 
remains the neglected disease of 
the AIDS pandemic,3 and there 
is an increasing group of young 
patients in low-income and middle-
income countries made healthy by 
successful treatment of underlying 
HIV, yet left permanently blind 
from undiagnosed or inadequately 
treated cytomegalovirus retinitis. 
Cytomegalovirus retinitis was second 
only to cataract as a cause of bilateral 
blindness in the Chiang Mai region 
of Thailand,4 and findings of a 
recent systematic review confirmed 
a substantial burden of disease, 
particularly in southeast Asia, with 
no apparent reduction in prevalence 
noted in the past decade.5 
On Oct 12, 2013, The Lancet editors6 
cited the “bold but attainable goal” 
of reducing the global prevalence of 
avoidable blindness. Cytomegalovirus 
retinitis is covered in every set of 
guidelines from the US Centers for 
Disease Control and Prevention, and 
now there is a unique opportunity for 
both the WHO Department of Blindness 
and WHO Department of AIDS to give 
full attention to this problem. Roche 
and the Geneva-based UNITAID-
supported Medicines Patent Pool have 
signed an agreement that provides 
a unique opportunity to reduce 
blindness and mortality in patients who 
present with late-stage HIV infection 
and cytomegalovirus retinitis or 
extraocular cytomegalovirus disease.7 
The agreement immediately makes 
valganciclovir available to treatment 
programmes at a price reduction of 
up to 90% in 138 low-income and 
middle-income countries. Additionally, 
increased use of valganciclovir might 
incentivise generic drug entry into the 
market, promising even deeper and 
more sustainable price reductions than 
at present.
Treatment with a simple pill, 
valganciclovir, is realistic in every 
setting, whereas the standard of care 
in low-income and middle-income 
countries—a weekly intraocular 
injection of ganciclovir8—is inadequate 
for several reasons and even 
intraocular injection is unavailable in 
most settings.3 However, a simple pill 
will not entirely solve the problem, 
and appropriate measures for crucial 
early detection of cytomegalovirus 
retinitis in the well-deﬁ ned vulnerable 
group of newly diagnosed patients 
with AIDS (those with CD4 cell counts 
below 100 cells per μL), are urgently 
needed. Unfortunately, with no 
mention of cytomegalovirus retinitis 
by WHO and no WHO guidelines 
on cytomegalovirus treatment, 
there has been little attention to 
treatment in national programmes, 
and systematic early screening is 
done in only one country, Myanmar 
(Burma), by enterprising non-
governmental organisations.9 Strong 
action by WHO and others now oﬀ ers 
opportunity to break the vicious cycle 
of underdiagnosis of cytomegalovirus 
retinitis and a lack of available, 
aﬀ ordable treatment. 
Valganciclovir  and systemic 
(rather than local) treatment 
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presenting with advanced HIV, as has 
been done in Myanmar.9
WHO needs to take action against 
cytomegalovirus retinitis for treat-
ment programmes to move towards 
elimination of preventable blindness 
and meet their targets for universal 
eye health.
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